Semaglutide—the active compound powering household blockbuster drugs Ozempic and Wegovy—delivers a surprising, vital shield for respiratory health. A massive UK health records study presented at the European Respiratory Society Congress in Barcelona linked the medication to a nearly 40% reduction in asthma attacks alongside a 20% drop in COPD flare-ups.
Imperial College London epidemiologist Professor Chloe Bloom led the research team, tracking over 80,000 patient records across four parallel cohorts. The team compared individuals taking GLP-1 medications against those prescribed standard sulfonylurea diabetes drugs, watching specifically for severe airway flare-ups.
Bloom noted that clinicians routinely prescribe GLP-1 receptor agonists for obesity and type 2 diabetes, while earlier lab work hinted at potential anti-inflammatory pathways within pulmonary tissue. Her team specifically sought real-world data to evaluate whether patients initiating these therapies suffered fewer emergency breathing complications.
The data spotlighted semaglutide as the clear standout across the entire drug class.
“The effect manifested most strongly with semaglutide, especially in people with asthma, where semaglutide therapy linked directly to nearly a 40% reduction in asthma attacks,” Bloom noted. “Semaglutide also drove a 20% reduction in COPD flare-ups.”
Despite these dramatic drops in patient hospital visits and acute episodes, researchers urged caution. Bloom warned that the observational findings carry limitations and should never alter clinical prescriptions immediately without prospective randomized controlled trials.
Outside medical specialists welcomed the revelations. Dr. Alexander Mathioudakis, an airways pharmacology specialist from the University of Manchester, hailed the investigation as an eye-opening milestone linking systemic metabolic stability to pulmonary resilience.
Mathioudakis underscored that airway diseases frequently worsen alongside obesity and metabolic dysfunction, conditions that standard respiratory care routinely overlooks. He called for future metabolic trials to formally integrate lung function, symptom frequency, and quality-of-life metrics into their endpoints.
Source: ScienceDaily
